Is CCL11 Blockade legal in the United States?

A chemokine that rises with age in human plasma and impairs neurogenesis in mice. There is human observational data linking it to cognition, and no trial of blocking it in anyone.

CCL11, also called eotaxin-1, came out of the 2011 Nature parabiosis study that founded the pro-ageing factor field. Using heterochronic parabiosis, the authors showed that blood-borne factors in an old systemic environment suppress adult neurogenesis and impair learning and memory in young mice.

Mechanism: In mice, raising peripheral CCL11 decreases adult hippocampal neurogenesis and impairs learning and memory, and reducing CCL11 mediates part of the benefit of environmental enrichment in the aged hippocampus. In humans, the established biology is the ordinary immunological one: CCL11 is an eosinophil chemoattractant acting through CCR3, central to allergic and eosinophilic inflammation.

Regulatory history: No CCL11-blocking therapy is approved for any indication and none is in a registered trial for ageing or cognition. CCL11 is measurable as a research and clinical laboratory analyte.

Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.

The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for CCL11 Blockade at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.